There is mounting evidence that Black patients develop more advanced liver cancers with less advanced liver disease. These findings have important implications for the future of liver cancer screening.

Free cholesterol accumulates in the liver in some patients with NAFLF and promotes the necroinflammation and fibrosis typical of NASH. Cholesterol-associated steatohepatitis (CASH) plays an important role in the development and progression of NASH. Randomized controlled trials are needed to demonstrate whether statins or statin/ezetimibe combination can effectively reverse steatohepatitis and liver fibrosis in patients with NASH.

We examined the potential of HBcrAg and HBsAg measured by ultrasensitive assays for predicting hepatocellular carcinoma (HCC) development in chronic hepatitis B patients treated with entecavir (ETV). The adjusted hazard ratio for HCC incidence was significantly lower in patients with HBcrAg ≤ 2.9 log U/mL at year 1 than in those in the high HBcrAg cohort. The measurement of HBcrAg via the ultrasensitive assay has a better potential for predicting HCC during antiviral treatment than the current HBcrAg assay.

Tele-hepatology is a safe, feasible, and reasonably effective tool for rendering health-care services using smartphones during the COVID-19 pandemic.

AMPK is a key cellular sensor that is activated in response to a variety of conditions that deplete energy levels. AMPK activity is reduced in NASH. Direct AMPK activation using PXL770, a clinical-stage investigational drug, improves the hallmarks of NASH and type 2 diabetes in rodent models.

In the randomized controlled trial, long-term ipragliflozin treatment ameliorates hepatic outcomes, including fibrosis, in patients with type 2 diabetes with NAFLD. Ipragliflozin also ameliorates obesity and glycemic control in patients with type 2 diabetes with NAFLD.

Inhibition of MAP3K1 activity prevents alcohol-induced liver injury.

In the present study, we observed that – although major interspecies differences remain – improved mouse models show up to 40% of the gene expression changes seen in liver tissue of human NAFLD or NASH, which is much higher than previously reported. Moreover, we identified gene sets consistently regulated in human and mouse chronic liver disease. Based on single-cell RNA-sequencing data set we mapped liver cell types to those genes and validated them by immunostaining.

CMTM4 stabilizes PD-L1 on liver cancer cells. CMTM4-low ICC/HCC, which expresses lower PD-L1, could be completely blocked by anti-PD-L1 mAb.

One-fourth of HCC patients receive no therapy and one-fifth of treated patients experience treatment delays. Both were associated with demographic, socioeconomic, clinical characteristics of patients, facility type, and regions. The association between therapeutic delay and survival was stage- and treatment-dependent. Therapeutic delay was associated with worse OS in patients who had early-stage HCC or received curative treatment.